# **Recommendations for Science in the Administrative Process**

For the last three decades, federal agencies have been criticized for not being clear about the role that science played in their decision-making processes.<sup>1</sup> In response to these criticisms, a number of efforts have been made by the Executive Branch and Congress to provide mechanisms that attempt to shore up the quality of the scientific process undergirding agency decision-making. Most recently, in 2009 President Obama issued a memorandum to the agencies directing that "To the extent permitted by law, there should be transparency in the preparation, identification, and use of scientific and technological information in policymaking."<sup>2</sup> "Each agency should [also] have appropriate rules and procedures to ensure the integrity of the scientific process within the agency."<sup>3</sup> This memorandum was further elaborated in 2010 by the Director of Office and Science Technology Policy (OSTP), John Holdren, who instructed agencies, among other things, to "communicate scientific and technological findings by including a clear explication of underlying assumptions; accurate contextualization of uncertainties; and a description of the probabilities associated with both optimistic and pessimistic case projections .... "<sup>4</sup> To effectuate this and a number of other responsibilities, agencies were asked to report back to OSTP with a report on the actions taken to develop and implement their scientific integrity policies by April, 2011.

At base, these initiatives demand heightened transparency of the agencies' use of science, a demand that is central to ensuring the basic accountability of agency regulation. If an agency isolates the role that scientific information plays in its ultimate decision and explains how it ensured that its scientific analysis was rigorous, then the public has a basis against which it can evaluate both the scientific and policy judgments embedded in the agency's decision. This

<sup>3</sup> *Id*.

<sup>&</sup>lt;sup>1</sup> See, e.g., NATIONAL RESEARCH COUNCIL, REVIEW OF THE ENVIRONMENTAL PROTECTION AGENCY'S DRAFT IRIS ASSESSMENT OF FORMALDEHYDE (2011) [hereinafter NAS, FORMALDEHYDE REPORT]; COMMITTEE ON RISK ASSESSMENT OF HAZARDOUS AIR POLLUTANTS, NATIONAL RESEARCH COUNCIL, SCIENCE AND JUDGMENT IN RISK ASSESSMENT (1994); NATIONAL RESEARCH COUNCIL, RISK ASSESSMENT IN THE FEDERAL GOVERNMENT: MANAGING THE PROCESS (1983) [hereinafter NAS, RISK ASSESSMENT]; BiPartisan Policy Center, Improving the Use of Science in Regulatory Policy 15-16, 41-42 (Aug. 2009); see also Advancing the Public Interest through Regulatory Reform: Recommendations for President-Elect Obama and the 111th Congress, c/o OMB Watch 26, 34, 47 (Nov. 2008).

<sup>&</sup>lt;sup>2</sup> Memorandum on Scientific Integrity from the Administration of Barack H. Obama for the Heads of Executive Departments and Agencies (Mar. 9, 2009), <u>http://www.gpo.gov/fdsys/pkg/DCPD-200900137/pdf/DCPD-200900137.pdf</u>.

<sup>&</sup>lt;sup>4</sup> Memorandum on Scientific Integrity from John P. Holdren for the Heads of Executive Departments and Agencies (Dec. 17, 2010), at pt. V [hereinafter John Holdren Scientific Integrity Memo] available at <a href="http://www.whitehouse.gov/sites/default/files/microsites/ostp/scientific-integrity-memo-12172010.pdf">http://www.whitehouse.gov/sites/default/files/microsites/ostp/scientific-integrity-memo-12172010.pdf</a> .

transparency thus allows those outside the agency to assess whether the agency's use of science comports with the authorizing law, the larger scientific record, and political preferences. This transparent decision process also advances other institutional and scientific goals, such as identifying promising areas for future research and serving as a bulwark against the politicization of science.

Some agencies are developing innovative ways to communicate how science informs their policies in sophisticated, yet accessible ways.<sup>5</sup> Agencies are also establishing processes that solicit both the expert and internal review of their work and that document the changes made in response to this input.<sup>6</sup> Integrity policies established by at least one agency allow staff to raise scientific differences with supervisors through various informal and formal mechanisms.<sup>7</sup> Finally, agencies increasingly have used the Internet to list the literature and other scientific evidence they relied on when making decisions.<sup>8</sup>

Despite these important innovations, agency decision-making processes would benefit from further improvements, and two sets of recommendations are proposed here. First, a number of external constraints on agency decision-making processes limit the ability of the agencies to improve their decision processes in keeping with the President's directive. An executive order caps the number of discretionary advisory committees that agencies can establish;<sup>9</sup> statutory barriers impede the public's access to studies informing agencies' scientific analysis;<sup>10</sup> presidential review processes can alter the science underlying a rule, but are protected as deliberative process;<sup>11</sup> and abbreviated statutory deadlines for rulemakings and the completion of agencies' scientific analyses<sup>12</sup> impede the ability of the agencies to develop rigorous and

<sup>8</sup> See the Health and Environmental Research Online (HERO) Database, last updated on February 8, 2012, available at <u>http://hero.epa.gov/</u>.

<sup>&</sup>lt;sup>5</sup> *See, e.g.*, Environmental Protection Agency (EPA), Policy Assessment for the Review of the Particulate Matter National Ambient Air Quality Standards, April 2011, *available at* <u>http://www.epa.gov/ttnnaaqs/standards/pm/data/20110419pmpafinal.pdf</u>. (a report that bridges science

and law in the development of air standards for particulates).

<sup>&</sup>lt;sup>6</sup> Under IRIS, EPA solicits written comments from external expert peer reviewers, the general public, and from other federal agencies. Its response to these written comments from external reviewers and the public is detailed in Appendix A of its risk assessment reports. For an example, see EPA, Toxicological Assessment of Acrylamide, March 2010, at Appendix A, *available at* http://www.epa.gov/iris/toxreviews/0286tr.pdf.

<sup>&</sup>lt;sup>7</sup> *See* Nuclear Regulatory Commission, Collaborative Work Environment Program, available at <u>http://www.nrc.gov/about-nrc/values/open-work-environment.html</u>.

<sup>&</sup>lt;sup>9</sup> Exec. Order No. 12,838, 58 Fed. Reg. 8207 (Feb. 10, 1993)

<sup>&</sup>lt;sup>10</sup> See, e.g., 7 U.S.C. § 136h(g)(1) (barring public access to most manufacturer-supplied research unless various conditions are satisfied).

<sup>&</sup>lt;sup>11</sup> See, e.g., Nina A. Mendelson, Disclosing "Political" Oversight of Agency Decision Making, 108 Mich. L. Rev. 1127, 1146-59 (2010) (discussing the lack of transparency of OMB review).

<sup>&</sup>lt;sup>12</sup> 16 U.S.C. § 1533(b)(5)(A)(i).

transparent processes for integrating science into regulation. One set of recommendations addresses these external constraints.

Second, while some agencies are innovative in their use of science, little of this innovation is recorded or shared across the government. A second set of recommendations attempts to catalog some of these innovations as best practices. While scientific and policy circumstances vary from program to program, thereby limiting the ability to apply one agency's innovations to others, certain presumptive "best practices" can and should be adopted by all agencies that engage in scientific decision-making.

### I. <u>External Barriers to the Integrity and Transparency of Science-Based</u> <u>Regulation</u>

### A. Presidential Review

- 1. The Office of Management and Budget (OMB) should establish scientific integrity policies for its own personnel that at least meet OSTP's minimum standards.<sup>13</sup> In addition, when significant changes are made during the course of OMB's review of a highly-influential science-based rule, OMB should comply with its own Final Information Quality Bulletin for Peer Review and engage external peer review to evaluate the scientific reliability of the change(s).<sup>14</sup>
- 2. OSTP should develop a government-wide dissent policy, modeled after the Nuclear Regulatory Commission's (NRC's) Collaborative Workplace Program, <sup>15</sup> which provides agency scientists and engineers with the right to dissent or withdraw their concurrence on scientific analyses to which they contributed if they feel the scientific information has been mischaracterized. This right should apply regardless of whether the change to the analysis originates in their own agency or another agency within the federal government (e.g., OMB). The dissent policy should also include a process for the adjudication and resolution of these scientific differences, like the NRC's Differing Professionals Opinion Program.
- 3. In keeping with his directive that "[t]o the extent permitted by law, there should be transparency in the preparation, identification, and use of scientific and technological information in policymaking,"<sup>16</sup> the President should issue an Executive Order directing OMB to refrain from applying the deliberative process privilege to its review of agencies'

<sup>&</sup>lt;sup>13</sup> See Holdren Memorandum, supra note 4.

<sup>&</sup>lt;sup>14</sup> See OMB, Final Information Quality Bulletin for Peer Review at 37-40 (Dec. 2004), *available at* <u>http://www.whitehouse.gov/sites/default/files/omb/memoranda/fy2005/m05-03.pdf</u>.

<sup>&</sup>lt;sup>15</sup> See Nuclear Regulatory Commission, Collaborative Work Environment Program, *available at* <u>http://www.nrc.gov/about-nrc/values/open-work-environment.html</u>.

<sup>&</sup>lt;sup>16</sup> See Obama Memorandum, *supra* note 2, at 1.

science-intensive regulations unless there are overwhelming national interests at stake, such as national security, personal privacy, or substantial trade secrets. In the alternative, the President should require by Executive Order that OMB or the agency originating the rule create a log of all changes made to an agency's draft rule during the course of OMB review and provide a reason for each change. This log and explanation of changes should be promptly placed in the administrative record. The President should also require by Executive Order that when OMB is engaged in the review of agency regulatory projects that are not economically significant as defined in Executive Order 12866, OMB should ensure that all of its communications with the agency are submitted in writing and placed in the public record.

4. OSTP should identify and publicize the best practices developed by agencies for transparently incorporating science into their regulatory decisions. In doing this, OSTP could establish a forum – e.g., a website or workshops – through which agencies can share innovations in their integration of science into policy.

#### B. Other External Impediments

- 5. Agencies are encouraged to ensure peer review of their scientific analyses,<sup>17</sup> yet the agencies currently encounter impediments to assembling external peer reviewers under Federal Advisory Committee Act. Caps that limit the number of discretionary FACA committees and other impediments to the use of FACA should be eliminated to enable agencies to use science advisory boards when they believe they are warranted.<sup>18</sup>
- 6. There are statutory and regulatory constraints (such as OMB's review which is protected as deliberative process) that limit the ability of the agencies to ensure that their decisions are scientifically robust and transparent in keeping with the President's Directive. OSTP and the agencies should identify these legal barriers that impede public access to the scientific information underlying agency analyses or otherwise block the agencies' development of scientifically robust decision-making processes. Once information has been collected on the nature and extent of these external barriers, OSTP should convene workshops and otherwise develop mechanisms for eliminating or at least minimizing these impediments. A critical complement to OSTP's request for agency integrity policies is OSTP's leadership in identifying and redressing significant external (statutory

<sup>&</sup>lt;sup>17</sup> See Obama Memorandum, *supra* note 2, at 1 (directing that "[w]hen scientific or technological information is considered in policy decisions, the information should be subject to well-established scientific processes, including peer review where appropriate, and each agency should appropriately and accurately reflect that information in complying with and applying relevant statutory standards"); Holdren Memorandum, *supra* note 4, at 1-2 (agencies should develop policies that ensure "that data and research used to support policy decisions undergo independent peer review by qualified experts, where feasible and appropriate, and consistent with law").

<sup>&</sup>lt;sup>18</sup> See Administrative Conference Recommendation 2011-7, *The Federal Advisory Committee Act—Issues and Proposed Reforms* (2011) (recommending rescission of the advisory committee cap created by Executive Order 12,838), *available at* <u>http://www.acus.gov/wp-</u>content/uploads/downloads/2011/12/Recommendation-2011-7-Federal-Advisory-Committee-Act.pdf.

and government-wide) impediments to the agencies' ability to use science transparently and rigorously in their regulatory products.

# II. <u>Best Practices for Agency Decision-Making Processes</u>

# A. Ensuring the Scientific Evidence used by the Agency is Publicly Accessible

- 7. In supporting its science-based regulatory decision, an agency should identify and make publicly available a list of the scientific literature it consulted, which ideally includes the literature it rejected as well as the literature it relied upon. This reference list should be posted online whenever possible.
- 8. When an agency relies on studies that are not published, it should post the studies on its website as soon as is practicable, subject to copyright and other legal restrictions. When this public transparency is not possible, these restrictions should be explained in the agency's individual analyses and possibly more generally in describing its regulatory program for the public.

# B. Agency Mechanisms to Enhance Scientific Integrity

- 9. Agency staff plays an important role in producing the agency's analyses. When possible, agency staff should be afforded some form of consensual authorship right for reports or analyses to which they contribute in a significant way. If authorship rights are not possible, attribution should be provided to individual agency staff for their contributions.
- 10. Agencies should have widely publicized, written policies that allow agency staff to dissent or express their non-concurrence on a technical analysis to which they contributed. Such dissenting staff members should be protected from reprisals. Any staff member's dissent or non-concurrence should be made part of the public record at the agency staff member's request.
- 11. Consistent with President Obama's directive, an agency's scientific analysis should be reviewed by other experts or subject to some mechanism of quality control, even if this oversight occurs wholly inside the agency. Agencies should not be impeded in their utilization of this expert peer review. Additionally and when possible, agencies should endeavor to explain how they ensured the rigorous review of their scientific products for each regulatory project.
- C. Agency Mechanisms to enhance Scientific Transparency
- 12. "Scientific progress depends upon honest investigation, open discussion, refined understanding, and a firm commitment to evidence."<sup>19</sup> Agencies should resist applying deliberative process protections to documents and communications that influenced the

<sup>&</sup>lt;sup>19</sup> Holdren Memorandum, *supra* note 4, at 1.

development of science-based regulatory projects. To the extent agencies do invoke the deliberative process privilege, they should justify so doing with respect to each document that is withheld from the public. Draft science-policy analyses, such as draft papers, can be made public with the disclaimer that they do not necessarily represent the policy or scientific position of the agency. Agencies should prepare an administrative record that advances this transparency goal by ensuring that the documents, meetings, and other deliberations that resulted in potentially significant changes to scientific assumptions or interpretations are made part of the administrative record. These administrative records should be posted on the internet when possible.

- 13. An agency's decision should be capable of being compared against the scientific record in a way that identifies the agency's most significant policy-based choices among the alternatives and that also identifies the agency's scientific judgments that were subject to rigorous expert review. At an early stage in their regulatory processes, agencies should identify the policy-relevant questions that can be informed by science, and when possible, provide a review of the available scientific evidence with respect to these policy-relevant questions. In applying this evidence to the policy questions at issue, the agency should also identify what their significant assumptions, choices of analytical techniques, and remaining uncertainties were and how different plausible choices would change the resulting policy decision. The agency should also endeavor to follow the model of the NAAQS policy assessment in bridging science and policy, although this step will likely involve more effort and experimentation.
- 14. OSTP should require agencies to provide a detailed and accessible description of the process that they utilize for integrating science into their decisions for each of their science-intensive programs. This includes a statement of how an agency evaluates the scientific information used in its analysis; how the agency makes that information available to reviewers and the public; how the analysis is reviewed by experts and interested parties; and how the agency ensures that the final decision can be compared against the scientific record. The agencies' description should be circulated as a publicly available memorandum to agency staff and ideally should be posted on the agency's website.
- 15. In regulatory settings, particularly in cases when agencies are not bound by judicially enforceable deadlines, the agencies should establish explicit stopping rules on regulatory projects, both with regard to when they will close their consideration of emerging research and when they chose to close scientific debate in order to reach a decision. External peer review bodies are particularly useful to agencies in establishing scientifically credible points at which debate should cease.